Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood|October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Medical Physics|April 30, 2022
Toward automatic beam angle selection for pencil-beam scanning proton liver treatments: A deep learning-based approachRobert Kaderka, Keng-Chi Liu, Lawrence Liu, et al.
Scientific Reports|August 22, 2019
Two Isoforms of the Guanine Nucleotide Exchange Factor, Daple/CCDC88C Cooperate as Tumor SuppressorsJason Ear, Ying Dunkel, Yash Mittal, et al.
Blood Advances|August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell LeukemiaGliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Quantification of Modifiable Risk Factors in Monoclonal Gammopathy of Undetermined Significance Progression to Multiple MyelomaMei Wang, Byron Sigel, Lawrence Liu, et al.
International Journal of Cancer|March 11, 2026
Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran populationMei Wang, Byron Sigel, Lawrence Liu, et al.
JAMA Network Open|February 7, 2025
Cumulative Excess Body Mass Index and MGUS Progression to MyelomaLawrence Liu, Nikhil Grandhi, Mei Wang, et al.
Molecular Medicine (Cambridge, Mass.)|February 1, 2013
Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyriaManisha Balwani, Dana Doheny, David F Bishop, et al.
Pageof 9